期刊
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY
卷 45, 期 1, 页码 15-24出版社
JAPANESE SOC LYMPHORETICULAR TISSUE RESEARCH
DOI: 10.3960/jslrt.45.15
关键词
NF-xB; lymphoma; two-stage carcinogenesis; Bcl-3; proteasome inhibitor
类别
Nuclear factor-kB (NF-xB) is a family of highly regulated dimeric transcription factors that play pivotal roles in inflammatory responses and immunological reactions. Although they are often activated concurrently, classical and alternative NF-xB activation pathways have distinct regulatory functions, producing secondary inflammatory responses and regulating lymphoid organ development, respectively. As NF-xB functions in the proliferation, differentiation, and survival of lymphocytes, increased activation also participates in the oncogenesis of many lymphoid malignancies. Aberrant NF-xB activation in these tumor cells results from genetic changes or the activation of NF-xB pathways by indirect mechanisms. Recent observations have suggested that NF-xB provides many of the requirements for cellular transformation. Bcl-3, a member of the IkB family, is overexpressed in t (2; 5)+ anaplastic large cell lymphoma due to genetic and epigenetic alterations. The different contributions of the classical and alternative NF-xB pathways to tumorigenesis, however, are not well understood. The clinical importance of NF-xB is also being recognized, with the approval of the NF-xB inhibitor bortezomib for treatment of advanced multiple myeloma. A better understanding of the molecular pathways involving NF-xB will surely contribute to more sophisticatedly targeted treatments for malignancies in the future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据